$CYTR $IBRX $SRNE Think about it this way: $IBRX is not $IBRX it is Altor Biosciences lead drug ALT 803 (which Soon Shiong has been sued for.) He has not filed a New Drug Application for ALT 803 [Anktiva] yet. $SRNE is suing $IBRX for "Catch n Kill" of Cynviloq. $CYTR has been waiting since 2017 for NDA of Aldoxorubicin - despite Dr. Sued Shiong's name being on the re-worked [New and Improved} Aldoxorubicin patent. What about the patent lawsuit regarding NK cells? $IBRX does not have 1 original drug. Anktiva [ALT 803] + Aldoxorubicin + Nk cells [and Cynviloq] have all been shelved or delayed because of Abraxane's reign. Aldoxorubicin is the next Abraxane - but because it was delayed - and no NDA has been filed $CYTR shareholders could piggyback on the $SRNE decision this week.